Lifecore Biomedical IncNASDAQ:LFCRNASDAQ FSI:E. Delinquent (Issuer missed regulatory filing deadline)
- LAST PRICE6.6400
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots6.3000/ 1
- Ask / Lots6.8000/ 10
- Open / Previous Close6.2100 / 6.6400
- Day Range
- 52 Week Range
- Volume256,407
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | LFCR |
|---|---|---|
| 09:32 ET | 200 | 6.21 |
| 09:36 ET | 700 | 6.23 |
| 09:43 ET | 100 | 6.19 |
| 09:50 ET | 1172 | 6.18 |
| 09:52 ET | 3400 | 6.225 |
| 09:54 ET | 1554 | 6.16 |
| 09:56 ET | 974 | 6.14 |
| 09:57 ET | 972 | 6.155 |
| 10:08 ET | 100 | 6.165 |
| 10:10 ET | 600 | 6.19 |
| 10:32 ET | 1500 | 6.1889 |
| 10:33 ET | 1338 | 6.139 |
| 10:37 ET | 1504 | 6.14 |
| 10:50 ET | 10982 | 6.19 |
| 10:51 ET | 1255 | 6.19 |
| 10:53 ET | 100 | 6.18 |
| 10:55 ET | 8733 | 6.21 |
| 10:57 ET | 3173 | 6.19 |
| 11:02 ET | 1000 | 6.19 |
| 11:06 ET | 100 | 6.18 |
| 11:13 ET | 200 | 6.17 |
| 11:15 ET | 900 | 6.19 |
| 11:20 ET | 300 | 6.19 |
| 11:22 ET | 100 | 6.195 |
| 11:36 ET | 1000 | 6.18 |
| 11:38 ET | 200 | 6.18 |
| 11:40 ET | 213 | 6.185 |
| 11:42 ET | 100 | 6.2 |
| 11:45 ET | 100 | 6.19 |
| 12:02 ET | 100 | 6.195 |
| 12:07 ET | 1237 | 6.18 |
| 12:12 ET | 100 | 6.18 |
| 12:16 ET | 405 | 6.16 |
| 12:18 ET | 300 | 6.165 |
| 12:20 ET | 600 | 6.17 |
| 12:34 ET | 1200 | 6.175 |
| 12:38 ET | 300 | 6.18 |
| 12:41 ET | 1809 | 6.18 |
| 12:45 ET | 900 | 6.18 |
| 12:52 ET | 100 | 6.19 |
| 01:10 ET | 100 | 6.19 |
| 01:12 ET | 682 | 6.18 |
| 01:19 ET | 844 | 6.17 |
| 01:21 ET | 300 | 6.16 |
| 01:24 ET | 100 | 6.15 |
| 01:26 ET | 100 | 6.15 |
| 01:30 ET | 100 | 6.15 |
| 01:32 ET | 794 | 6.1825 |
| 01:39 ET | 7821 | 6.21 |
| 01:44 ET | 5994 | 6.19 |
| 01:46 ET | 100 | 6.2 |
| 01:50 ET | 200 | 6.2 |
| 01:53 ET | 200 | 6.2 |
| 01:57 ET | 100 | 6.205 |
| 02:02 ET | 1000 | 6.18 |
| 02:04 ET | 818 | 6.18 |
| 02:20 ET | 100 | 6.17 |
| 02:22 ET | 100 | 6.16 |
| 02:29 ET | 2098 | 6.12 |
| 02:31 ET | 100 | 6.14 |
| 02:47 ET | 300 | 6.175 |
| 02:54 ET | 1100 | 6.16 |
| 03:03 ET | 100 | 6.16 |
| 03:05 ET | 100 | 6.16 |
| 03:07 ET | 110 | 6.16 |
| 03:16 ET | 7643 | 6.27 |
| 03:18 ET | 100 | 6.27 |
| 03:20 ET | 300 | 6.3 |
| 03:21 ET | 600 | 6.3 |
| 03:23 ET | 150 | 6.274 |
| 03:25 ET | 100 | 6.275 |
| 03:27 ET | 1322 | 6.31 |
| 03:30 ET | 11171 | 6.37 |
| 03:32 ET | 2946 | 6.3178 |
| 03:34 ET | 1743 | 6.36 |
| 03:36 ET | 985 | 6.39 |
| 03:38 ET | 100 | 6.39 |
| 03:41 ET | 2156 | 6.43 |
| 03:43 ET | 38507 | 6.58 |
| 03:45 ET | 16797 | 6.64 |
| 03:48 ET | 1800 | 6.625 |
| 03:50 ET | 2991 | 6.64 |
| 03:52 ET | 3531 | 6.595 |
| 03:54 ET | 4705 | 6.62 |
| 03:56 ET | 1864 | 6.62 |
| 03:57 ET | 4955 | 6.625 |
| 03:59 ET | 8217 | 6.64 |
Yesterday
Apr 24, 2024
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Lifecore Biomedical, Inc. - LFCR, from 3:48PM ET on Wednesday Apr 24, 2024 by Dow Jones
3:48PM ET on Wednesday Apr 24, 2024 by Dow Jones
Apr 23, 2024
Apr 21, 2024
Apr 20, 2024
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Lifecore Biomedical, Inc. - LFCR, from 12:00PM ET on Saturday Apr 20, 2024 by Dow Jones
12:00PM ET on Saturday Apr 20, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Lifecore Biomedical Inc | 193.4M | -3.1x | --- |
Nektar Therapeutics | 253.4M | -0.9x | --- |
Aytu Biopharma Inc | 15.6M | -0.7x | --- |
Kali Inc | 1.0K | 0.0x | --- |
OptiNose Inc | 104.2M | -2.9x | --- |
Journey Medical Corp | 47.4M | -10.0x | --- |
Company Information
Lifecore Biomedical, Inc. is a fully integrated contract development and manufacturing organization (CDMO). The Company designs, develops, manufactures and sells differentiated products for biomaterials markets and license technology applications to partners. The Company offers highly differentiated capabilities in the development, fill and finish of sterile, injectable-grade pharmaceutical products in syringes and vials. It is involved in the manufacture of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a spectrum of medical conditions and procedures. The Company uses its fermentation process and aseptic formulation and filling expertise to develop HA-based products for multiple applications and to take advantage of non-HA devices and drug opportunities.
Contact Information
- Headquarters
- 3515 Lyman BoulevardCHASKA, MN, United States 55318
- Phone
- 952-368-4300
- Fax
- 302-636-5454
Executives
- Non-Executive Independent Chairman of the Board
- Craig Barbarosh
- Director
- James Hall
- Chief Financial Officer, Company Secretary
- John Morberg
- Director
- Nat Calloway
- Director
- Christopher Kiper
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $193.4M |
|---|---|
Revenue (TTM) | $103.3M |
Shares Outstanding | 30.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.99 |
EPS | $-2.12 |
Book Value | $1.16 |
P/E Ratio | -3.1x |
Price/Sales (TTM) | 1.9 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -44.10% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
